Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models

Endocrinology

Volumn 152, Issue 12, 2011, Pages 4550-4561

  Gravina, Giovanni Luca ^a   Marampon, Francesco ^a,d   Piccolella, Margherita ^c   Motta, Marcella ^c   Ventura, Luca ^b   Pomante, Roberto ^e   Popov, Vladimir M ^d   Zani, Bianca M ^a   Pestell, Richard G ^d   Tombolini, Vincenzo ^f   Jannini, Emmanuele A ^a   Festuccia, Claudio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Mazzini Hospital   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; EPIGENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR XENOGRAFT; UPREGULATION;

ANILIDES; CELL LINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG RESISTANCE; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 82355190886     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1056     Document Type: Article

References (29)

1. Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH 2009 Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol 55:563-574
2. Morgentaler A, Traish AM 2009 AM Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55:310-320
3. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889-895
4. Knudsen KE, Penning TM 2010 Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 21:315-324
5. Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T 2009 Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 56: 594-605
6. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade Jr JL, Bennett CL, Scher HI 2004 American society of clinical oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22:2927-2941 (Pubitemid 41079913)
7. Craft N, Shostak Y, Carey M, Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285 (Pubitemid 29124362)
8. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45 (Pubitemid 33741879)
9. Gelmann EP 2002 Molecular biology of the androgen receptor. Amplification and co-regulators of androgen receptor gene in prostate cancer. J Clin Oncol 20:3001-3015
10. Golias Ch, Iliadis I, Peschos D, Charalabopoulos K 2009 Amplification and co-regulators of androgen receptor gene in prostate cancer. Exp Oncol 31:3-8
11. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG 2009 Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139:1069-1083
12. Popov VM, Wang C, Shirley LA, Rosenberg A, Li S, Nevalainen M, Fu M, Pestell RG 2007 The functional significance of nuclear receptor acetylation. Steroids 72:221-230 (Pubitemid 46273505)
13. Leader JE, Wang C, Fu M, Pestell RG 2006 Epigenetic regulation of nuclear steroid receptors. Biochem Pharmacol 72:1589-1596 (Pubitemid 44666731)
14. Nelson WG, De Marzo AM, Yegnasubramanian S 2009 Epigenetic alterations in human prostate cancers. Endocrinology 150:3991-4002
15. Feinberg AP, Tycko B 2004 The history of cancer epigenetics. Nat Rev Cancer 4:143-153 (Pubitemid 38198742)
16. Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR 2008 Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res 6:365-374
17. Perry AS, Foley R, Woodson K, Lawler M 2006 The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer 13:357-377 (Pubitemid 43886663)
18. Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR 2008 Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res 8:1365-1374
19. Zorn CS, Wojno KJ, McCabe MT,Kuefer R, Gschwend JE, Day ML 2007 5-Aza-2′-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res 13:2136-2143 (Pubitemid 46649883)
20. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J 2009 Ligand- independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16-22
21. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM 2011 Intragenic rearrangement and alteredRNAsplicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71:2108-2117
22. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Ricevuto E, Vicentini C, Bologna M 2007 In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate 67:1255-1264 (Pubitemid 47435773)
23. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, Vicentini C, BolognaM2007 Bicalutamide increases phospho- Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer 14:601-611 (Pubitemid 350074050)
24. Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de VitoM,Vicentini C, BolognaM2008 Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate 68:793-801 (Pubitemid 351632951)
25. Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C 2010 5-azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 70:1166-1178
26. Gravina GL, Festuccia C, Angelucci A, Poletti A, Capuano D, Vicentini C, Motta M, Bologna M 2004 Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Int J Oncol 25:97-104
27. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M 2008 Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 68:965-974. (Pubitemid 351794161)
28. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Ricevuto E, Vicentini C, Bologna M 2007 In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate 67:1255-1264 (Pubitemid 47435773)
29. Gravina GL, Festuccia C, Galatioto GP, Muzi P, Angelucci A, Ronchi P, CostaAM,BolognaM,VicentiniC2007 Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology 70:728-733